Revisiting the Pharmacodynamic Uroselectivity of α1-Adrenergic Receptor Antagonists
Open Access
- 1 October 2019
- journal article
- research article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 371 (1) , 106-112
Abstract
α1-adrenoceptor (AR) antagonists are widely used for the relief of urinary retention secondary to benign prostatic hyperplasia (BPH). While the five FDA-approved α1-AR antagonists (terazosin, doxazosin, alfuzosin, tamsulosin and silodosin) share similar efficacy, they differ in tolerability with reports of ejaculatory dysfunction. The aim of the present work was to revisit their α1-AR subtype selectivity as well as of LDT5, a compound previously described as a multi-target antagonist of α1A-/α1D-AR and 5-HT1A receptors, and to estimate their affinity for D2, D3 and 5-HT1A receptors, putatively involved in ejaculatory dysfunction. Competition binding assays were performed with native (D2, 5-HT1A) or transfected (human α1A-, α1B-, α1Dt-AR and D3) receptors for determination of drug9s affinities. Tamsulosin and silodosin have the highest affinities for α1A-AR, but only silodosin is clearly a selective α1A-AR antagonist with Ki ratios of 25.3 and 50.2, for the α1D-AR and α1B-AR, respectively. Tamsulosin, silodosin and LDT5, but not terazosin, doxazosin and alfuzosin, have high affinity for the 5-HT1AR (Ki around 5-10 nM), behaving as antagonists. We conclude that the uroselectivity of tamsulosin is not explained by its too low selectivity for the α1A- vs. α1B-AR and that its affinity for D2 and D3 receptors is probably too low for explaining the ejaculatory dysfunction reported for this drug. Present data also support the design of »better-than-LDT5» new multi-target lead compounds with pharmacokinetics selectivity based on poor brain penetration and that could prevent hyperplastic cell proliferation and BPH progression. SIGNIFICANCE STATEMENT Present work revisits the uroselectivity of the five FDA-approved α1 adrenoceptor antagonists for the treatment of benign prostatic hyperplasia (BPH). Contrarily to what has been claimed by some, our results indicate that the uroselectivity of tamsulosin is probably not fully explained by its too weak selectivity for the α1A vs. α1B adrenoceptors. We also show that tamsulosin affinity for D3 and 5-HT1A receptors is probably too low for explaining the ejaculatory dysfunction reported for this drug. Based on our lead compound LDT5, present data support the search for a multi-target antagonist of α1A-α1D and 5-HT1A receptors with poor brain penetration as an alternative for BPH treatment.Keywords
This publication has 42 references indexed in Scilit:
- EAU Guidelines on the Treatment and Follow-up of Non-neurogenic Male Lower Urinary Tract Symptoms Including Benign Prostatic ObstructionEuropean Urology, 2013
- Differential Phosphorylation, Desensitization, and Internalization of α1A−Adrenoceptors Activated by Norepinephrine and OxymetazolineMolecular Pharmacology, 2013
- Reducing safety-related drug attrition: the use of in vitro pharmacological profilingNature Reviews Drug Discovery, 2012
- Tamsulosin Potently and Selectively Antagonizes Human Recombinant .ALPHA.1A/1D-Adrenoceptors: Slow Dissociation from the .ALPHA.1A-Adrenoceptor May Account for Selectivity for .ALPHA.1A-Adrenoceptor over .ALPHA.1B-Adrenoceptor SubtypeBiological and Pharmaceutical Bulletin, 2012
- Tamsulosin shows a higher unbound drug fraction in human prostate than in plasma: a basis for uroselectivity?British Journal of Clinical Pharmacology, 2011
- α1‐Adrenoceptor subtypes and lower urinary tract symptomsInternational Journal of Urology, 2008
- Identification of binding sites of prazosin, tamsulosin and KMD-3213 with α1-adrenergic receptor subtypes by molecular modelingLife Sciences, 2002
- Selective and sustained occupancy of prostatic α1-adrenoceptors by oral administration of KMD-3213 and its plasma concentration in ratsJournal of Pharmacy and Pharmacology, 2002
- Identification of α1-adrenoceptor subtypes present in the human prostateLife Sciences, 1994
- Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reactionBiochemical Pharmacology, 1973